Core Viewpoint - A securities class action lawsuit has been filed against Centene Corporation for allegedly making materially false and misleading statements regarding its business operations and market performance during the specified Class Period from December 12, 2024, to June 30, 2025 [1][2]. Group 1: Allegations Against Centene - The lawsuit claims that Centene's management misrepresented the company's marketplace share, indicating lower-than-expected enrollment and increased market morbidity [2]. - It is alleged that the statements made by Centene's management about the company's business and prospects were materially false and lacked a reasonable basis throughout the Class Period [2]. Group 2: Lead Plaintiff Process - Investors in Centene have until September 8, 2025, to apply to be appointed as lead plaintiff representatives in the class action [3]. - The lead plaintiff will represent the interests of all class members and is typically the investor or group of investors with the largest financial stake in the case [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the case and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]. - The firm encourages affected Centene investors to reach out for more information regarding the lawsuit [4].

Group 1 - Centene Corp (CNC) and Molina Healthcare Inc (MOH) are experiencing stock price increases following Berkshire Hathaway's investment in UnitedHealth Group (UNH) [1] - CNC shares rose by 4.4% to $28.11, marking its third gain in four sessions, after previously hitting a low of $24 due to a negative outlook for 2025 [2] - MOH shares increased by 3.4% to $165.03, recovering from a low of $150 after a significant drop post-earnings [3] Group 2 - Despite recent challenges, options traders are showing a bullish sentiment towards both CNC and MOH, with CNC's put/call open interest ratio in the 10th percentile of its annual range and MOH's ratio higher than only 19% of readings from the past year [4]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 2: Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states served by Centene [4]. Group 3: Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Insights - Membership growth is a fundamental driver of Centene Corporation's earnings model, with each additional enrollee contributing directly to premium revenues despite rising costs [1][2][3] - As of June 30, 2025, Centene's total membership reached 28 million, supported by strong enrollment in Marketplace, Individual and Commercial Group, Medicare, and Medicare PDP plans [2][9] - The company is expanding its Medicare Advantage presence through its WellCare platform, introducing plans in new counties and enhancing star ratings [2][3] Membership Growth and Strategy - Centene's membership growth enhances its scale, profitability, and resilience, allowing it to navigate market uncertainties with a diverse payer mix [3] - Ongoing membership momentum is driven by product innovation, geographic expansion, and community-focused retention strategies [3] - Although Medicaid enrollment has softened, the company continues to see growth in other segments, particularly in Medicare Advantage [2][3] Competitive Landscape - Humana Inc. is also experiencing membership growth, particularly in Medicare Advantage, with a projected increase of 175,000-250,000 in state-based contract membership in 2025 [4] - UnitedHealth Group is witnessing robust growth in medical membership, driven by demand for commercial and government-supported health plans [5] Financial Performance - Centene's shares have lost 55.3% year to date, underperforming the industry average [8] - The company trades at a forward price-to-earnings ratio of 7.2, significantly below the industry average of 12.1 [9][12] - Recent consensus estimates for Centene's EPS have been revised downward for the third and fourth quarters of 2025, indicating potential challenges ahead [13][15]

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centene Corporation (NYSE: CNC). CONTACT: CLASS PERIOD: December 12, 2024 to June 30, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors be ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Group 1: Allegations and Impact - The class period for the lawsuit is from December 12, 2024, to June 30, 2025 [3]. - The complaint alleges that Centene's management made overwhelmingly positive statements while concealing material adverse facts about the company's performance [3]. - Following the withdrawal of the 2025 guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Group 2: Financial Adjustments - Centene's preliminary analysis indicated that its overall market growth across 22 states, representing 72% of its marketplace membership, was lower than expected [3]. - The company adjusted its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75 [3]. Group 3: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by September 8, 2025 [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 2: Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 3: Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - Allegations state that Centene misled investors about its business prospects, creating a false impression of reliable revenue outlook and growth while actual enrollment rates and morbidity were lower than expected [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3] Group 2 - Following the announcement on July 1, 2025, Centene's stock price dropped from $56.65 to $44.78 per share, a decline of over 40% [3] - Shareholders are encouraged to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [4] - Robbins LLP has been dedicated to shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5]

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/centene-corporation-lawsuit-submi ...

Core Viewpoint - Centene Corporation is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between December 12, 2024, and June 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided overly positive statements while concealing material adverse facts regarding the company's enrollment and morbidity rates [2]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [2]. - Following this announcement, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 8, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].